Immunization with a Syngeneic Tumor Infected with Recombinant Vaccinia Virus Expressing Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Induces Tumor Regression and Long-Lasting Systemic Immunity

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 449-459

  McLaughlin, Joanne P ^a,b   Abrams, Scott ^a   Kantor, Judy ^a   Dobrzanski, Mark J ^a   Greenbaum, Jordan ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Biomira   (Canada)

Author keywords

Antitumor immunity; GM CSF; GM CSF vaccine; Recombinant vaccinia

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0030831107     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00004     Document Type: Article

References (56)

1. Metcalf D. Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 1991;254:529-33.
2. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991;77:1131-45.
3. Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989;7:159-67.
4. Scarffe JH. Emerging clinical uses for GM-CSF. Ear J Cancer 1991;27:1493-504.
5. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM. Granulocyte-macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987;166:1484-98.
6. Heufler C, Koch F, Schuler G. Granulocyte-macrophage colony-stimulating factor and interleukin-1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988;167:700-5.
7. Romani N, Koide S, Crowley M, et al. Presentation of exogenous protein antigens by dendritic cells to T-cell clones. J Exp Med 1989;169:1169-78.
8. Larson CP, Ritchie SC, Hendrix R, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152:5208-19.
9. Tao MH, Levy R. Idiotype-granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma [see comments]. Nature 1993;362:755-8.
10. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinjection with plasmids expressing cytokines. Immunity 1995;2:129-35.
11. Taglietti MR, Rouzier-Panis M, Aymard M, Garaud JJ. A doubleblind placebo-controlled study to assess the immune response to flu vaccine following a single dose of rhGM-CSF in elderly people. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, 1994.
12. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996;23:101-7.
13. Lin R, Tarr PE, Jones TC. Considerations regarding the use of cytokines in active specific immunotherapy of cancer. Vaccine Res 1996;5:41-51.
14. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3563.
15. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:662-8.
16. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760-5.
17. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994;54:3516-20.
18. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996;56:2191-8.
19. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-l-transduced, lymphoma cells primes idio-type-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-65.
20. Conry RM, Wisera G, LoBuglio AF, et al. Selected strategies to augment polynucleotide immunization. Gene Ther 1996;3:67-74.
21. Qin HX, Chatterjee SK. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996;7:1853-60.
22. Ju DW, Cao XT, Acres B. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte-macrophage colony-stimulating factor-gene-encoded vaccinia virus. J Cancer Res Clin Oncol 1996;122:716-22.
23. Coupar BEH, Andrew ME, Boyle DB. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 1988;68:1-10.
24. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 1983;25:21-8.
25. Stephens EB, Compans RW, Earle P, Moss B. Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. EMBO J 1986;5:237.
26. Lafreniere R, Rosenberg SA. A novel approach to the generation and identification of experimental hepatic métastasés in a murine model. J Natl Cancer Inst 1986;76:309-22.
27. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-9.
28. Fox BA, Spiess PJ, Kasid A, et al. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 1990;9:499-511.
29. Miyatake ST, Otsuka T, Yokota T, Lee F, Aria K. Structure of the chromosomal gene for granulocyte-macrophage colony-stimulating factor: comparison of the mouse and human genes. EMBO J 1985;4:2561-8.
30. Hirano T, Yasukawa T, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to 46. produce immunoglobulin. Nature 1986;324:73-6.
31. Holbrook NL, Smith KA, Fornace AJ Jr, Comeau CM, Wiskocil RL, Crabtree GR. T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci USA 1984;81:1634-8.
32. Kaufman H, Schlom J, Kantor J, et al. A recombinant vaccinia 47 virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-7.
33. Ao 1982;79:7415-9.
34. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D. Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 1980;52:1036-1047.
35. Aarden LA, DeGrood ER, Schaep OL, Lansdorf PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987;17:1411-7.
36. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978;120:2027-32.
37. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
38. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of the murine T-cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983;131:2445-51.
39. Sarmiento M, Glasebrook AL, Fitch FW. IgG and IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T-cell-mediated cytolysis in the absence of complement. J Immunol 1978;125:2665-72.
40. Jaffee EM, Thomas MC, Huang A Y-C, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of 54. paracrine cytokine vaccines. J Immunother 1996;19:176-83.
41. Gosselin EJ, Wradell K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/ 55. macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 1993;151:1482-7.
42. Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and 56. peptide-based vaccines. Blood 1996;88:202-10.
43. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the ma lignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
44. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397.
45. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effects of interleukin-4. Science 1992;257:548-51.
46. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor α, and γ-interferon gene or admixed with conventional agents. Cancer Res 1994;54:6022-6.
47. Area MJ, Krauss JC, Strome SE, Careron MJ, Chang AE. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996;42:237.
48. + CTL response to an influenza hemagglutinin epitope reflects limited T cell availability. J Immunol 1996;157:505-11.
49. Handman E, Burgess AW. Stimulation of granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979;122:1223-34.
50. Ho JL, Reed SG, Wick EA, Giordano M. Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 1990;162:224-30.
51. Moss B. Vaccinia virus: a tool for research and development. Science 1991;252:1662-7.
52. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte-macrophage colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995;121:587-92.
53. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte-macrophage colony-stimulating factor regulates the distribution and differentiated state of dendritic cells: Langerhans cells in human lung and lung cancer. J Clin Invest 1993;91:566-76.
54. Grabbe S, Bruvers S, Gallo FL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-61.
55. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1828-33.
56. Bausero MA, Panokaltsis-Mortari A, Blazer BR, Katsanis E. Effective immunization against neuroblastoma using doubletransduced tumor cells secreting GM-CSF and interferony. J Immunother 1996;19:113-24.